Using CAR Gamma-Delta T Cells to Treat Solid Tumors

A Single Arm, Open Label, Dose-escalation Phase I and Dose-expansion Phase IIa Clinical Study to Evaluate the Feasibility, Safety, and Efficacy of Allogeneic Chimeric Antigen Receptor (CAR) Gamma-Delta T Cells CAR001 in Subjects with Relapsed/refractory Solid Tumors

This study is testing a new type of immune cell therapy to see if it can help people with hard-to-treat solid tumors like lung cancer and breast cancer feel better and fight their cancer.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Ever Supreme Bio Technology Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy, radiation, prednisone
• Locations: 1 site (Taichung, Non-US)
• Trial ID: NCT06150885 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and efficacy of CAR001, an allogeneic CAR Gamma-Delta T cell therapy, in patients with relapsed or refractory solid tumors. It consists of a phase I dose-escalation part to determine the maximum tolerated dose and a phase IIa part focusing on the efficacy in specific cancers such as non-small cell lung cancer, triple negative breast cancer, colorectal cancer, and glioblastoma multiforme. The study aims to assess tumor response rates and monitor the levels of CAR-positive γδT cells in the blood over time.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with relapsed or refractory solid tumors that express PD-L1 and have failed at least two lines of standard therapy.

Not a fit: Patients with solid tumors that do not express PD-L1 or those who have not undergone prior standard therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could provide a new treatment option for patients with difficult-to-treat solid tumors.

How similar studies have performed: Other studies using CAR T cell therapies have shown promising results, indicating potential for success with this novel approach.

Eligibility criteria

Inclusion Criteria:

1. Male or female subjects aged ≥ 18 years
2. For phase I part, subjects with histologically confirmed diagnosis of solid tumor with expression of PD-L1 ≥ 1% and are relapsed/refractory to at least two lines of standard-of-care therapy. For phase IIa part, subjects with histologically confirmed diagnosis of TNBC, NSCLC, CRC or GBM with expression of PD-L1 ≥ 1%, and are relapsed/refractory to at least two lines of standard-of-care therapy.
3. With at least one measurable lesion as defined by RECIST1.1 (for TNBC, NSCLC or CRC) or RANO (for GBM)
4. Able to understand and sign the ICF
5. Have a life expectancy of \> 12 weeks
6. ECOG performance status ≤ 1
7. Recovered from any previous therapy related toxicity to ≤ grade 2 at screening
8. With adequate renal function: serum creatinine ≤ 1.5 X ULN; eGFR \> 50 ml/min
9. With adequate liver function: ALT, AST, and ALP ≤ 3X ULN or ≤ 5 X ULN if liver metastases; and total bilirubin ≤ 1.5X ULN or ≤ 3 X ULN if due to Gilbert's disease
10. With PT and PTT ≤ 1.5X ULN
11. With adequate hematopoietic function:

    * ANC ≥ 1,000 cells/μl
    * Platelets ≥ 75,000 counts/μl
    * Total WBC ≥ 2,000 cells/μl
    * Hemoglobin ≥ 8 g/dL

Exclusion Criteria:

1. Has received any allogeneic cell therapy before screening
2. With known or suspected to be hypersensitivity to CAR001 or its excipients, such as DMSO or human serum albumin
3. With more than one kind of active diagnosed primary cancer
4. With active infection requiring systemic medication
5. With medical conditions who are receiving systemic steroid therapy \>10 mg prednisone/day or equivalent dose, or other immune-suppressants in the past 2 weeks
6. Has been diagnosed as HIV positive (confirmed by anti-HIV and nucleic acid test)
7. With acute cardiovascular disease; NYHA classification ≥ 3; or history of myocardial infarction during the past 6 months; or has active uncontrolled arterial hypertension by medical history. Per investigator's judgment, would not make participation appropriate
8. With historical or current auto-immune diseases, such as rheumatoid arthritis, type I diabetes, psoriasis or systemic lupus erythematosus
9. Has uncontrolled psychiatric disorder by medical history
10. Has CNS diseases except GBM or stroke
11. Has received any investigational therapy from another clinical study within 4 weeks
12. Inability to undergo radiological assessment, such as MRI or CT for any reason
13. Has received radiotherapy or chemotherapy within 2 weeks (but palliative radiation therapy (R/T) for pain control are allowed)
14. Not suitable to participate the trial as judged by the investigator
15. Female subject of childbearing potential who:

    * Is lactating; or
    * Has a positive pregnancy test result at eligibility checking; or
    * Refuses to adopt at least two form of birth control from signing informed consent to 1 year after the last administration of CAR001.
16. Male subject with a female spouse/partner who is of childbearing potential refuses to adopt at least two forms of birth control from signing informed consent to 1 year after the last administration of CAR001.

For exclusion criteria #15 and #16, acceptable forms of birth control include:

* Established use of oral, injected, or implanted hormonal methods of contraception that have comparable efficacy (failure rate \< 1 %), for example hormone vaginal ring or transdermal hormone contraception
* Placement of an intrauterine device or intrauterine system
* Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)

Where this trial is running

Taichung, Non-US

• China Medical University Hospital — Taichung, Non-US, Taiwan (Recruiting)

Study contacts

• Study coordinator: Sammi Hsu

Conditions Solid Tumor